Techniques for Immune Function Analysis Application Handbook 1St Edition
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Human Vδ2 T Cells Are a Major Source of Interleukin-9
Human Vδ2 T cells are a major source of interleukin-9 Christian Petersa, Robert Häslerb, Daniela Wescha, and Dieter Kabelitza,1 aInstitute of Immunology, University Hospital Schleswig-Holstein Campus Kiel, D-24105 Kiel, Germany; and bInstitute of Clinical Molecular Biology, University Hospital Schleswig-Holstein Campus Kiel, D-24105 Kiel, Germany Edited by Willi K. Born, National Jewish Health, Denver, CO, and accepted by Editorial Board Member Philippa Marrack September 12, 2016 (received for review May 13, 2016) Vδ2Vγ9 T cells are the dominant γδ T-cell subset in human periph- Vδ2 T cells produce different cytokines, can be converted into + eral blood. Vδ2 T cells recognize pyrophosphate molecules derived forkhead box protein P3 (FoxP3) regulatory cells (20, 21), and from microbes or tumor cells; hence, they play a role in antimicro- may acquire professional antigen-presenting capacity (22). Depend- bial and antitumor immunity. TGF-β, together with IL-15, induces ing on priming conditions, Vδ2 T cells can secrete IFN-γ,IL-4,IL- a regulatory phenotype in Vδ2 T cells, characterized by forkhead 17, and IL-22, and thus recapitulate cytokine patterns of well-defined box protein P3 (FoxP3) expression and suppressive activity on CD4 functional Th subsets (23, 24). T-cell activation. We performed a genome-wide transcriptome Here, we identified peripheral blood Vδ2Tcellsasamajorsource analysis and found that the same conditions (TGF-β plus IL-15) of IL-9. In the presence of TGF-β and IL-15 but the absence of IL-4, strongly enhanced the expression of additional genes in Vδ2T high levels of IL-9 were secreted already 4 d after initial in vitro ac- cells, including IKAROS family zinc finger 4 (IKZF4; Eos), integrin tivation. -
Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3
RX Zhang, et al ORIGINAL ARTICLE Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3 1 Department of Otolaryngology, Huadong Hospital, Fudan University, Shanghai, China 2 Department of Otolaryngology , Jinan General Hospital of PLA, Shandong, China 3 Department of Otolaryngology, Changhai Hospital, Second Military Medical University, Shanghai, China ■ Abstract Objective: To analyze the roles of chemokines and their receptors in the pathogenesis of allergic rhinitis by observing the complementary DNA (cDNA) expression of the chemokines and their receptors in the nasal mucosa of patients with and without allergic rhinitis, using gene chips. Methods: The total RNAs were isolated from the nasal mucosa of 20 allergic rhinitis patients and purifi ed to messenger RNAs, and then reversely transcribed to cDNAs and incorporated with samples of fl uorescence-labeled with Cy5-dUPT (rhinitis patient samples) or Cy3- dUTP (control samples of nonallergic nasal mucosa). Thirty-nine cDNAs of chemokines and their receptors were latticed into expression profi le chips, which were hybridized with probes and then scanned with the computer to study gene expression according to the different fl uorescence intensities. Results: The cDNAs of the following chemokines were upregulated: CCL1, CCL2, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL17, CCL18, CCL19, CCL24, and CX3CL1 in most of the allergic rhinitis sample chips. CCR2, CCR3, CCR4, CCR5, CCR8 and CX3CR1 were the highly expressed receptor genes. Low expression of CXCL4 was found in these tissues. Conclusion: The T helper cell (TH) immune system is not well regulated in allergic rhinitis. -
Edinburgh Research Explorer
Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S. -
Therapeutic and Prophylactic Use of Oral, Low-Dose Ifns in Species of Veterinary Interest: Back to the Future
veterinary sciences Review Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future Sara Frazzini 1 , Federica Riva 2,* and Massimo Amadori 3 1 Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy; [email protected] 2 Dipartimento di Medicina Veterinaria, Università degli Studi di Milano, 26900 Lodi, Italy 3 Rete Nazionale di Immunologia Veterinaria, 25125 Brescia, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0250334519 Abstract: Cytokines are important molecules that orchestrate the immune response. Given their role, cytokines have been explored as drugs in immunotherapy in the fight against different pathological conditions such as bacterial and viral infections, autoimmune diseases, transplantation and cancer. One of the problems related to their administration consists in the definition of the correct dose to avoid severe side effects. In the 70s and 80s different studies demonstrated the efficacy of cytokines in veterinary medicine, but soon the investigations were abandoned in favor of more profitable drugs such as antibiotics. Recently, the World Health Organization has deeply discouraged the use of antibiotics in order to reduce the spread of multi-drug resistant microorganisms. In this respect, the use of cytokines to prevent or ameliorate infectious diseases has been highlighted, and several studies show the potential of their use in therapy and prophylaxis also in the veterinary field. In this review we aim to review the principles of cytokine treatments, mainly IFNs, and to update the experiences encountered in animals. Keywords: veterinary immunotherapy; cytokines; IFN; low dose treatment; oral treatment Citation: Frazzini, S.; Riva, F.; Amadori, M. -
The 'C3ar Antagonist' SB290157 Is a Partial C5ar2 Agonist
bioRxiv preprint doi: https://doi.org/10.1101/2020.08.01.232090; this version posted August 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. The ‘C3aR antagonist’ SB290157 is a partial C5aR2 agonist Xaria X. Li1, Vinod Kumar1, John D. Lee1, Trent M. Woodruff1* 1School of Biomedical Sciences, The University of Queensland, St Lucia, 4072 Australia. * Correspondence: Prof. Trent M. Woodruff School of Biomedical Sciences, The University of Queensland, St Lucia, 4072 Australia. Ph: +61 7 3365 2924; Fax: +61 7 3365 1766; E-mail: [email protected] Keywords: Complement C3a, C3aR, SB290157, C5aR1, C5aR2 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.01.232090; this version posted August 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abbreviations used in this article: BRET, bioluminescence resonance energy transfer; BSA, bovine serum albumin; C3aR, C3a receptor C5aR1, C5a receptor 1; CHO-C3aR, Chinese hamster ovary cells stably expressing C3aR; CHO-C5aR1, Chinese hamster ovary cells stably expressing C5aR1; DMEM, Dulbecco's Modified Eagle's Medium; ERK1/2, extracellular signal-regulated kinase 1/2; FBS, foetal bovine serum; HEK293, human embryonic kidney 293 cells; HMDM, human monocyte-derived macrophage; i.p., intraperitoneal; i.v., intravenous; rhC5a, recombinant human C5a; RT, room temperature; S.E.M. -
BD Biosciences New RUO Reagents - November 2020
BD Biosciences New RUO reagents - November 2020 Reactivity Description Format Clone Size Cat. number Hu CD133 FITC W6B3C1 100µg 567029 Hu CD133 FITC W6B3C1 25µg 567033 Hu CD39 PE A1/CD39 100Tst 567156 Hu CD39 PE A1/CD39 25Tst 567157 Hu KIR2DL1/S1/S3/S5 PE HP-MA4 100Tst 567158 Hu KIR2DL1/S1/S3/S5 PE HP-MA4 25Tst 567159 Hu IL-22 Alexa Fluor® 647 MH22B2 100µg 567160 Hu IL-22 Alexa Fluor® 647 MH22B2 25µg 567161 Hu CD99 R718 TU12 50µg 751651 Hu CD161 R718 DX12 50µg 751652 Hu CD116 R718 HGMCSFR-M1 50µg 751653 Hu HLA-G R718 87G 50µg 751670 Hu CD27 R718 O323 50µg 751686 Hu CD80 (B7-1) R718 2D10.4 50µg 751737 Hu Integrin αvβ5 R718 ALULA 50µg 751738 Hu CD266 (Tweak-R) R718 ITEM-4 50µg 751739 Hu ErbB3 (HER-3) R718 SGP1 50µg 751799 Hu TCR Vβ5.1 R718 LC4 50µg 751816 Hu CD123 (IL-3Ra) R718 6H6 50µg 751844 Hu CD1a R718 SK9 50µg 751847 Hu CD20 R718 L27 50µg 751849 Hu Disial GD2 R718 14.G2A 50µg 751851 Reactivity Description Format Clone Size Cat. number Hu CD71 R718 L01.1 50µg 751853 Hu CD278 (ICOS) R718 DX29 50µg 751854 Hu B7-H4 R718 MIH43 50µg 751857 Hu CD53 R718 HI29 50µg 751858 Hu CD197 (CCR7) R718 2-L1-A 50µg 751859 Hu CD197 (CCR7) R718 3D12 50µg 751861 Hu CD31 R718 L133.1 50µg 751863 Hu EGF Receptor R718 EMAB-134 50µg 751864 Hu CD8b R718 2ST8.5H7 50µg 751867 Hu CD31 R718 MBC 78.2 50µg 751869 Hu CD162 R718 KPL-1 50µg 751873 Hu CD24 R718 ML5 50µg 751874 Hu CD159C (NKG2C) R718 134591 50µg 751876 Hu CD169 (Siglec-1) R718 7-239 50µg 751877 Hu CD16b R718 CLB-GRAN11.5 50µg 751880 Hu IgM R718 UCH-B1 50µg 751881 Hu CD275 R718 2D3/B7-H2 50µg 751883 Hu CD307e -
Bioinformatics Identification of CCL8/21 As Potential Prognostic
Bioscience Reports (2020) 40 BSR20202042 https://doi.org/10.1042/BSR20202042 Research Article Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment 1,* 2,* 3 4 5 1 Bowen Chen , Shuyuan Zhang ,QiuyuLi, Shiting Wu ,HanHe and Jinbo Huang Downloaded from http://portlandpress.com/bioscirep/article-pdf/40/11/BSR20202042/897847/bsr-2020-2042.pdf by guest on 28 September 2021 1Department of Breast Disease, Maoming People’s Hospital, Maoming 525000, China; 2Department of Clinical Laboratory, Maoming People’s Hospital, Maoming 525000, China; 3Department of Emergency, Maoming People’s Hospital, Maoming 525000, China; 4Department of Oncology, Maoming People’s Hospital, Maoming 525000, China; 5Department of Medical Imaging, Maoming People’s Hospital, Maoming 525000, China Correspondence: Shuyuan Zhang ([email protected]) Background: Breast cancer (BC) is the most common malignancy among females world- wide. The tumor microenvironment usually prevents effective lymphocyte activation and infiltration, and suppresses infiltrating effector cells, leading to a failure of the host toreject the tumor. CC chemokines play a significant role in inflammation and infection. Methods: In our study, we analyzed the expression and survival data of CC chemokines in patients with BC using several bioinformatics analyses tools. Results: The mRNA expression of CCL2/3/4/5/7/8/11/17/19/20/22 was remark- ably increased while CCL14/21/23/28 was significantly down-regulated in BC tis- sues compared with normal tissues. Methylation could down-regulate expression of CCL2/5/15/17/19/20/22/23/24/25/26/27 in BC. Low expression of CCL3/4/23 was found to be associated with drug resistance in BC. -
Supplementary Table 2 Supplementary Table 1
Supplementary table 1 Rai/ Binet IGHV Cytogenetic Relative viability Fludarabine- Sex Outcome CD38 (%) IGHV gene ZAP70 (%) Treatment (s) Stage identity (%) abnormalities* increase refractory 1 M 0/A Progressive 14,90 IGHV3-64*05 99,65 28,20 Del17p 18.0% 62,58322819 FCR n.a. 2 F 0/A Progressive 78,77 IGHV3-48*03 100,00 51,90 Del17p 24.8% 77,88052021 FCR n.a. 3 M 0/A Progressive 29,81 IGHV4-b*01 100,00 9,10 Del17p 12.0% 36,48 Len, Chl n.a. 4 M 1/A Stable 97,04 IGHV3-21*01 97,22 18,11 Normal 85,4191657 n.a. n.a. Chl+O, PCR, 5 F 0/A Progressive 87,00 IGHV4-39*07 100,00 43,20 Del13q 68.3% 35,23314039 n.a. HDMP+R 6 M 0/A Progressive 1,81 IGHV3-43*01 100,00 20,90 Del13q 77.7% 57,52490626 Chl n.a. Chl, FR, R-CHOP, 7 M 0/A Progressive 97,80 IGHV1-3*01 100,00 9,80 Del17p 88.5% 48,57389901 n.a. HDMP+R 8 F 2/B Progressive 69,07 IGHV5-a*03 100,00 16,50 Del17p 77.2% 107,9656878 FCR, BA No R-CHOP, FCR, 9 M 1/A Progressive 2,13 IGHV3-23*01 97,22 29,80 Del11q 16.3% 134,5866919 Yes Flavopiridol, BA 10 M 2/A Progressive 0,36 IGHV3-30*02 92,01 0,38 Del13q 81.9% 78,91844953 Unknown n.a. 11 M 2/B Progressive 15,17 IGHV3-20*01 100,00 13,20 Del11q 95.3% 75,52880995 FCR, R-CHOP, BR No 12 M 0/A Stable 0,14 IGHV3-30*02 90,62 7,40 Del13q 13.0% 13,0939004 n.a. -
ATP-Binding and Hydrolysis in Inflammasome Activation
molecules Review ATP-Binding and Hydrolysis in Inflammasome Activation Christina F. Sandall, Bjoern K. Ziehr and Justin A. MacDonald * Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada; [email protected] (C.F.S.); [email protected] (B.K.Z.) * Correspondence: [email protected]; Tel.: +1-403-210-8433 Academic Editor: Massimo Bertinaria Received: 15 September 2020; Accepted: 3 October 2020; Published: 7 October 2020 Abstract: The prototypical model for NOD-like receptor (NLR) inflammasome assembly includes nucleotide-dependent activation of the NLR downstream of pathogen- or danger-associated molecular pattern (PAMP or DAMP) recognition, followed by nucleation of hetero-oligomeric platforms that lie upstream of inflammatory responses associated with innate immunity. As members of the STAND ATPases, the NLRs are generally thought to share a similar model of ATP-dependent activation and effect. However, recent observations have challenged this paradigm to reveal novel and complex biochemical processes to discern NLRs from other STAND proteins. In this review, we highlight past findings that identify the regulatory importance of conserved ATP-binding and hydrolysis motifs within the nucleotide-binding NACHT domain of NLRs and explore recent breakthroughs that generate connections between NLR protein structure and function. Indeed, newly deposited NLR structures for NLRC4 and NLRP3 have provided unique perspectives on the ATP-dependency of inflammasome activation. Novel molecular dynamic simulations of NLRP3 examined the active site of ADP- and ATP-bound models. The findings support distinctions in nucleotide-binding domain topology with occupancy of ATP or ADP that are in turn disseminated on to the global protein structure. -
Interleukin-9 Regulates Macrophage Activation in the Progressive Multiple Sclerosis Brain
Donninelli et al. Journal of Neuroinflammation (2020) 17:149 https://doi.org/10.1186/s12974-020-01770-z RESEARCH Open Access Interleukin-9 regulates macrophage activation in the progressive multiple sclerosis brain Gloria Donninelli1†, Inbar Saraf-Sinik1,2†, Valentina Mazziotti3, Alessia Capone1,4, Maria Grazia Grasso5, Luca Battistini1, Richard Reynolds6, Roberta Magliozzi3,6*† and Elisabetta Volpe1*† Abstract Background: Multiple sclerosis (MS) is an immune-mediated, chronic inflammatory, and demyelinating disease of the central nervous system (CNS). Several cytokines are thought to be involved in the regulation of MS pathogenesis. We recently identified interleukin (IL)-9 as a cytokine reducing inflammation and protecting from neurodegeneration in relapsing–remitting MS patients. However, the expression of IL-9 in CNS, and the mechanisms underlying the effect of IL-9 on CNS infiltrating immune cells have never been investigated. Methods: To address this question, we first analyzed the expression levels of IL-9 in post-mortem cerebrospinal fluid of MS patients and the in situ expression of IL-9 in post-mortem MS brain samples by immunohistochemistry. A complementary investigation focused on identifying which immune cells express IL-9 receptor (IL-9R) by flow cytometry, western blot, and immunohistochemistry. Finally, we explored the effect of IL-9 on IL-9-responsive cells, analyzing the induced signaling pathways and functional properties. Results: We found that macrophages, microglia, and CD4 T lymphocytes were the cells expressing the highest levels of IL-9 in the MS brain. Of the immune cells circulating in the blood, monocytes/macrophages were the most responsive to IL-9. We validated the expression of IL-9R by macrophages/microglia in post-mortem brain sections of MS patients. -
IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis This information is current as Xin Zhang, Nazanin Kiapour, Sahil Kapoor, Tabish Khan, of September 27, 2021. Madhan Thamilarasan, Yazhong Tao, Stephanie Cohen, Ryan Miller, Raymond A. Sobel and Silva Markovic-Plese J Immunol published online 24 July 2019 http://www.jimmunol.org/content/early/2019/07/23/jimmun ol.1900311 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2019/07/23/jimmunol.190031 Material 1.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2019 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published July 24, 2019, doi:10.4049/jimmunol.1900311 The Journal of Immunology IL-11 Induces Encephalitogenic Th17 Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis Xin Zhang,* Nazanin Kiapour,* Sahil Kapoor,* Tabish Khan,* Madhan Thamilarasan,* Yazhong Tao,* Stephanie Cohen,† Ryan Miller,‡ Raymond A. -
Anti-GPR15, N-Terminal (G4283)
Anti-GPR15, N-Terminal produced in rabbit, affinity isolated antibody Catalog Number G4283 Synonym: Anti-BOB Product Profile Immunoblotting: a working dilution of 1:500-1:2,000 is Product Description recommended using human heart tissue lysate, Jurkat Anti-GPR15, N-Terminal is produced in rabbit using a (human T cell leukemic) cell lysate, or A549 (human peptide corresponding to the N-terminal amino acids lung alveolar epithelial) cell lysate. A band of ~50 kDa 13-28 of human GPR15 (BOB) as immunogen.1 The is detected. sequence differs from African green monkey and pig- tailed macaque BOB by one amino acid.2 Note: In order to obtain best results in different tech- niques and preparations we recommend determining Anti-GPR15, N-Terminal recognizes GPR15 by optimal working concentrations by titration test. immunoblotting. It is reactive in human, mouse, and rat. References GRP15 (BOB) and STRL33.3 (Bonzo) are seven- 1. Heiber, M., et al., A novel human gene encoding a transmembrane, G-protein-coupled receptors with G-protein-coupled receptor (GPR15) is located on sequence similarity to chemokine receptors and to chromosome 3. Genomics, 32, 462-465 (1996). chemokine receptor-like orphan receptors.1, 2, 3 The 2. Deng, J.K., et al., Expression cloning of new DNA sequence of human and monkey GPR15 receptors used by simian and human immuno- (G protein-coupled receptor 15) /BOB (brother of deficiency viruses. Nature, 388, 296-300 (1997). Bonzo) has been cloned.1, 2 GRP15 (BOB) functions as 3. Liao, F., et al., STRL33, A novel chemokine a co-receptor for simian immunodeficiency virus (SIV), receptor-like protein, functions as a fusion cofactor strains of HIV-2, and M-tropic HIV-1.2, 4, 5, 6 GPR15 for both macrophage-tropic and T cell line-tropic (BOB) is expressed in lymphoid tissues and colon.1, 2 HIV-1.